Identification of a Gene Signature to Aid Treatment Decisions by Integrated Analysis of Mutated Genes Between Primary and Metastatic Prostate Cancer

por Li, Qinyu, Xiao, Xueyan, Chen, Bingliang, Song, Guoda, Zeng, Kai, Miao, Jianping
Publicado 2022

Dual-Functional Tunable Metasurface for Meta-Axicon with a Variable Depth of Focus and Continuous-Zoom Metalens

por Wang, Chang, Sun, Yan, Yu, Zeqing, Liu, Xinyu, Chen, Bingliang, Zhang, Yang, Zheng, Zhenrong
Publicado 2023

A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy

por Kuang, Zhihui, Li, Li, Zhang, Pan, Chen, Bingliang, Wu, Min, Ni, Haiqing, Yi, Shuai, Zou, Jia, Liu, Junjian
Publicado 2020

LMO3 downregulation in PCa: A prospective biomarker associated with immune infiltration

por Xu, Wenchao, Sun, Taotao, Wang, Jiaxin, Li, Hao, Chen, Bingliang, Zhou, Yingjian, Wang, Tao, Wang, Shaogang, Liu, Jihong, Jiang, Hongyang
Publicado 2022

A predictive signature based on enhancer RNA associates with immune infiltration and aids treatment decision in clear cell renal cell carcinoma

por Li, Qinyu, Xiao, Xueyan, Chen, Bingliang, Song, Guoda, Zeng, Kai, Li, Beining, Miao, Jianping, Liu, Chaofan, Luan, Yang, Liu, Bo
Publicado 2022

Integrated analysis to identify the AC005154.6/hsa-miR-29c-3p/CCNL2 axis as a novel prognostic biomarker associated with immune infiltration in prostate cancer

por Li, Qinyu, Chen, Bingliang, Song, Guoda, Zeng, Kai, Chen, Xin, Miao, Jianping, Yuan, Xianglin, Liu, Jihong, Wang, Zhihua, Liu, Bo
Publicado 2022

Comprehensive analysis to identify the RP11–478C19.2/ E2F7 axis as a novel biomarker for treatment decisions in clear cell renal cell carcinoma

por Zeng, Kai, Song, Guoda, Chen, Bingliang, Gao, Xintao, Liu, Chaofan, Miao, Jianping, Ruan, Yajun, Luan, Yang, Chen, Xin, Liu, Jihong, Li, Qinyu, Liu, Bo
Publicado 2022

Identification of Calcium Channel-Related Gene P2RX2 for Prognosis and Immune Infiltration in Prostate Cancer

por Li, Qinyu, Wu, Bili, Daba, Motuma, Gao, Xintao, Chen, Bingliang, Song, Guoda, Zeng, Kai, Miao, Jianping, Yuan, Xianglin, Liu, Jihong, Wang, Zhihua, Liu, Bo
Publicado 2022

Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer

por Zhang, Shuang, Zhang, Min, Wu, Weiwei, Yuan, Zhijun, Tsun, Andy, Wu, Min, Chen, Bingliang, Li, Jia, Miao, Xiaoniu, Miao, Xiaoliang, Liu, Xiaolin, Yu, Dechao, Liu, Junjian
Publicado 2018

Lower Urinary Tract Symptoms and Sexual Dysfunction in Male: A Systematic Review and Meta-Analysis

por Song, Guoda, Wang, Min, Chen, Bingliang, Long, Gongwei, Li, Hao, Li, Rui, Liu, Zhuo, Wei, Chao, Wang, Tao, Wang, Shaogang, Liu, Jihong, Zhang, Yucong, Liu, Xiaming
Publicado 2021

Inflammatory bowel disease is associated with worse sexual function: a systematic review and meta-analysis

por Chen, Bingliang, Zhou, Bingyan, Song, Guoda, Li, Hao, Li, Rui, Liu, Zhuo, Wei, Chao, Wang, Tao, Wang, Shaogang, Ma, Delin, Liu, Jihong, Yuan, Xiaoyi, Liu, Xiaming
Publicado 2022

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit

por Wang, Jie, Fei, Keke, Jing, Hua, Wu, Zhihai, Wu, Weiwei, Zhou, Shuaixiang, Ni, Haiqing, Chen, Bingliang, Xiong, Yan, Liu, Yanpeng, Peng, Bo, Yu, Dechao, Jiang, Haiping, Liu, Junjian
Publicado 2019

Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody

por Wang, Yan, Pan, Donghui, Huang, Chenrong, Chen, Bingliang, Li, Mingzhu, Zhou, Shuaixiang, Wang, Lizhen, Wu, Min, Wang, Xinyu, Bian, Yicong, Yan, Junjie, Liu, Junjian, Yang, Min, Miao, Liyan
Publicado 2020

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

por Jiang, Haiping, Ni, Haiqing, Zhang, Pan, Guo, Xiaoli, Wu, Min, Shen, Haoran, Wang, Jie, Wu, Weiwei, Wu, Zhihai, Ding, Jiazheng, Tang, Rong, Zhou, Shuaixiang, Chen, Bingliang, Yu, Michael, Jing, Hua, Liu, Junjian
Publicado 2021

Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity

por Qiao, Yunqian, Qiu, Yangmin, Ding, Jie, Luo, Nana, Wang, Hao, Ling, Xiaomin, Sun, Jiya, Wu, Zhihai, Wang, Yisen, Liu, Yanpeng, Guo, Feifei, Sun, Ta, Shen, Wanwan, Zhang, Min, Wu, Dongdong, Chen, Bingliang, Xu, Wei, Wang, Xuan
Publicado 2021

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis (Adv. Sci. 30/2023)

por Lin, Wu, Zhang, Yingzi, Yang, Yan, Lin, Ben, Zhu, Mengjia, Xu, Jinling, Chen, YiRan, Wu, Weiwei, Chen, Bingliang, Chen, Xiangliu, Liu, Jin, Wang, Haohao, Teng, Fei, Yu, Xiongfei, Wang, Haiyong, Lu, Jun, Zhou, Quan, Teng, Lisong
Publicado 2023

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis

por Lin, Wu, Zhang, Yingzi, Yang, Yan, Lin, Ben, Zhu, Mengjia, Xu, Jinling, Chen, YiRan, Wu, Weiwei, Chen, Bingliang, Chen, Xiangliu, Liu, Jin, Wang, Haohao, Teng, Fei, Yu, Xiongfei, Wang, Haiyong, Lu, Jun, Zhou, Quan, Teng, Lisong
Publicado 2023

Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity

por Liu, Huisi, Wu, Weiwei, Sun, Gangyu, Chia, Tiongsun, Cao, Lei, Liu, Xiaodan, Guan, Jian, Fu, Fenggen, Yao, Ying, Wu, Zhihai, Zhou, Shuaixiang, Wang, Jie, Lu, Jia, Kuang, Zhihui, Wu, Min, He, Luan, Shao, Zhiyuan, Wu, Dongdong, Chen, Bingliang, Xu, Wenqing, Wang, Zhizhi, He, Kaijie
Publicado 2022